{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:04:46Z","timestamp":1789571086078,"version":"build-2803163510"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"JSPS KAKENHI","award":["25\u00a0K10874"],"award-info":[{"award-number":["25\u00a0K10874"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This frequentist network meta-analysis was conducted to compare vornorexant (VOR) and lemborexant (LEM) in terms of efficacy, tolerability, and safety outcomes in adults with insomnia disorder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Efficacy outcomes evaluated at weeks 1 and 2 included subjective time to sleep onset (sTSO), which served as the primary outcome at week 2, as well as subjective total sleep time (sTST), subjective wake after sleep onset (sWASO), and subjective sleep efficiency. Tolerability outcome was treatment discontinuation due to adverse events. Safety outcomes included the incidence of death, suicidal behavior or ideation, at least one adverse event, somnolence, fatigue, dizziness, falls, headache, nightmares, cataplexy, and sleep paralysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This network meta-analysis included seven trials (n\u00a0=\u20092805, average age\u2009=\u200955.14\u00a0years, 69.22% female). Treatment arms comprised VOR 5\u00a0mg\/day (VOR5), VOR 10\u00a0mg\/day (VOR10), LEM 5\u00a0mg\/day (LEM5), LEM 10\u00a0mg\/day (LEM10), and placebo. All active treatments were associated with significantly greater improvements in sTSO at week 2 than placebo. The mean differences in sTSO at week 2 were\u2009\u221211.997\u00a0min (95% CI, \u221215.236 to \u22128.757) for LEM5, \u221214.856\u00a0min (95% CI, \u221218.038 to \u221211.674) for LEM10, \u221211.364\u00a0min (95% CI, \u221214.733 to \u22127.996) for VOR5, and\u2009\u2212\u20099.758\u00a0min (95% CI, \u221213.186 to \u22126.330) for VOR10. LEM5, LEM10, and VOR5 demonstrated significant improvements across all efficacy outcomes at weeks 1 and 2 over placebo. However, although VOR10 did not demonstrate superiority over placebo for sWASO at weeks 1 and 2, it was superior to placebo for all other efficacy outcomes. LEM5 and LEM10 were associated with a higher incidence of at least one adverse event and somnolence compared with placebo, whereas no significant differences in tolerability or safety outcomes were observed for VOR5 or VOR10 versus placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dosage variations could influence both the clinical efficacy and safety profile of these agents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ijnp\/pyag047","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:57:30Z","timestamp":1788289050000},"source":"Crossref","is-referenced-by-count":0,"title":["Vornorexant versus lemborexant for insomnia disorder: a systematic review and network meta-analysis"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9237-2236","authenticated-orcid":false,"given":"Taro","family":"Kishi","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Fujita Health University School of Medicine , Toyoake, Aichi 470-1192 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Sakuma","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fujita Health University School of Medicine , Toyoake, Aichi 470-1192 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8785-9330","authenticated-orcid":false,"given":"Tsuyoshi","family":"Kitajima","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fujita Health University School of Medicine , Toyoake, Aichi 470-1192 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakao","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fujita Health University School of Medicine , Toyoake, Aichi 470-1192 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"2026091610313782700_ref1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyaf077","article-title":"Current and novel dual orexin receptor antagonists for the treatment of insomnia: the emergence of vornorexant","volume":"28","author":"Chino","year":"2025","journal-title":"Int J Neuropsychopharmacol"},{"key":"2026091610313782700_ref2"},{"key":"2026091610313782700_ref3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41398-025-03439-8","article-title":"Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis","volume":"15","author":"Kishi","year":"2025","journal-title":"Transl Psychiatry"},{"key":"2026091610313782700_ref4","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-026-03974-y","article-title":"Optimal use of dual orexin receptor antagonists for insomnia: a network meta-analysis perspective","volume":"16","author":"Kishi","year":"2026","journal-title":"Transl Psychiatry"},{"key":"2026091610313782700_ref5","first-page":"2024","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (Updated August 2024)","author":"Higgins"},{"key":"2026091610313782700_ref6","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"2026091610313782700_ref7"},{"key":"2026091610313782700_ref8"},{"key":"2026091610313782700_ref9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"2026091610313782700_ref10","volume-title":"Netmeta: Network Meta-Analysis Using Frequentist Methods (R Package Version 0.9-5)","author":"R\u00fccker"},{"key":"2026091610313782700_ref11","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaf291","article-title":"Efficacy and safety of vornorexant in Japanese patients with insomnia: a randomized, placebo-controlled phase 3 pivotal study","volume":"49","author":"Uchiyama","year":"2025","journal-title":"Sleep"},{"key":"2026091610313782700_ref12"},{"key":"2026091610313782700_ref13","doi-asserted-by":"publisher","first-page":"e1918254","DOI":"10.1001\/jamanetworkopen.2019.18254","article-title":"Comparison of Lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial","volume":"2","author":"Rosenberg","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2026091610313782700_ref14","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa123","article-title":"Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2","volume":"43","author":"Karppa","year":"2020","journal-title":"Sleep"},{"key":"2026091610313782700_ref15","doi-asserted-by":"crossref","first-page":"108722","DOI":"10.1016\/j.sleep.2025.108722","article-title":"A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial of lemborexant in adults with insomnia disorder","volume":"139","author":"Mi","year":"2026","journal-title":"Sleep Med"},{"key":"2026091610313782700_ref16"},{"key":"2026091610313782700_ref17","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.5664\/jcsm.6800","article-title":"Lemborexant, a dual orexin receptor antagonist (DORA) for the treatment of insomnia disorder: results from a Bayesian, adaptive, randomized, double-blind","volume":"13","author":"Murphy","year":"2017","journal-title":"Placebo-Controlled Study J Clin Sleep Med"},{"key":"2026091610313782700_ref18","first-page":"540","article-title":"Short-term effects of lemborexant on subjective sleep parameters in older adults with chronic insomnia","volume":"51","author":"Moline","year":"2026","journal-title":"ACNP 64th Annual Meeting, Poster Abstracts P818 Neuropsychopharmacol"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyag047\/70895842\/pyag047.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/29\/9\/pyag047\/70895842\/pyag047.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/29\/9\/pyag047\/70895842\/pyag047.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:31:46Z","timestamp":1789569106000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/doi\/10.1093\/ijnp\/pyag047\/8778741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyag047","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,9,1]]},"article-number":"pyag047"}}